Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer’s disease. Its therapeutic use is listed as antidotes and diagnostic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Swiss Blue, Chromosmon, Urolene blue and Tetramethylene Blue. Its PubChem CID is 6099.
Methylene blue
| CAS No | 61-73-4 |
|---|---|
| Molecular Formula | C16H18ClN3S |
| Molecular Weight | 319.90 g/mol |
| Synonyms | [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.
The listed CAS number is 61-73-4.
The listed molecular formula is C16H18ClN3S.
The listed molecular weight is 319.90 g/mol.
[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride.
The source lists Swiss Blue, Chromosmon, Urolene blue and Tetramethylene Blue.